FAM82A Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-79510
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Synthetic peptide directed towards the middle region of human FAM82A. Peptide sequence: RAPMNGHCHLWYAVLCGYVSEFEGLQNKINYGHLFKEHLDIAIKLLPEEP The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Scientific Data Images for FAM82A Antibody
![Western Blot: FAM82A Antibody [NBP1-79510]](https://resources.bio-techne.com/images/products/FAM82A-Antibody-Western-Blot-NBP1-79510-img0003.jpg "Western Blot: FAM82A Antibody [NBP1-79510]")
Western Blot: FAM82A Antibody [NBP1-79510]
Western Blot: FAM82A Antibody [NBP1-79510] - Titration: 0.2-1 ug/ml, Positive Control: 293T cell lysate.Applications for FAM82A Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: FAM82A
Alternate Names
family with sequence similarity 82, member A1, member A, UNQ9371/PRO34163
Gene Symbol
RMDN2
UniProt
Additional FAM82A Products
Product Documents for FAM82A Antibody
Product Specific Notices for FAM82A Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...